FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Midodrine HCl Tablets
Status: Discontinuation
»Therapeutic Categories: Cardiovascular

Expand all

Apotex Corp. (New 10/16/2017)

Company Contact Information:
800-706-5575

Presentation Posting Date Related Information
Midodrine Hydrochloride Tablets 2.5 mg (bottle of 100) (NDC 60505-1320-01) 10/16/2017
Midodrine Hydrochloride Tablets 5 mg (bottle of 100)(NDC 60505-1321-01) 10/16/2017
Midodrine Hydrochloride Tablets 10 mg (bottle of 100)(NDC 60505-1325-01) 10/16/2017

Impax Laboratories (New 08/25/2017)

Company Contact Information:
877-994-6729

Presentation Posting Date Related Information
2.5 mg; 100 tablets/bottle (NDC 0115-4211-01) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
2.5 mg; 500 tablets/bottle (NDC 0115-4211-02) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
2.5 mg; 1000 tablets/bottle (NDC 0115-4211-03) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
5 mg; 100 tablets/bottle (NDC 0115-4222-01) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
5 mg; 500 tablets/bottle (NDC 0115-4222-02) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
5 mg; 1000 tablets/bottle (NDC 0115-4222-03) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
10 mg; 100 tablets/bottle (NDC 0115-4233-01) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
10 mg; 500 tablets/bottle (NDC 0115-4233-02) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.
10 mg; 1000 tablets/bottle (NDC 0115-4233-03) 08/25/2017 A business decision was made to discontinue manufacture of the drug product. This product discontinuation is not related to product quality, safety, or efficacy. The anticipated final date for marketing is February 2018.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English